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The prognosis of advanced stage rhabdomyosarcoma (RMS) is still sobering. In recent years, outcome has not been
further improved by conventional therapy. Therefore, novel treatment options such as macrophage-directed immuno-
therapy have to be investigated. The aim of this study was to analyze the phagocytosis of RMS cells by macrophages and
to modulate the susceptibility using monoclonal antibodies and cytotoxic drugs.
Expression of the macrophage activating ligand calreticulin and CD47, the counterpart of the inhibitory receptor SIRPa,
was analyzed with Affymetrix mRNA expression arrays and immunohistochemistry on 11 primary RMS samples. Results
were verified in two RMS cell lines using flow cytometry and immunocytochemistry. Macrophage cytotoxic activity was
quantified by a MTT colorimetric assay in co-culture experiments of RMS cells with monocyte-derived, GM-CSF stimulated
macrophages.
Gene expression analysis and immunohistochemistry revealed a high expression of CD47 and calreticulin in alveolar and
embryonal RMS tissue specimens. Extracellular expression of CD47 on RMS cell lines was confirmed by flow cytometry,
whereas calreticulin was exclusively detected in the endoplasmatic reticulum. After co-culturing of RMS cells with
macrophages, viability dropped to 50–60%. Macrophage-mediated cytotoxicity was not influenced by a blocking antibody
against CD47. However, susceptibility was significantly enhanced after pre-treatment of RMS cells with the anthracycline
drug doxorubicin. Furthermore, translocation of calreticulin onto the cell surface was detected by flow cytometry.
The immunologic effect of doxorubicin may improve the efficacy of adoptive cellular immunotherapy and
chemotherapy of childhood RMS.
Introduction
Rhabdomyosarcoma (RMS) is the most frequent pediatric soft
tissue sarcoma. It represents 3–4% of all pediatric cancers
1 and
7–8% of all solid malignant tumors in children.
2 There exist two
main histopathological subtypes of this malignancy, embryonal
RMS (RME) and alveolar RMS (RMA) with completely different
tumor biology.
3 RMS tumors are currently treated by multimodal
therapies, including surgery, radiotherapy and systemic chemo-
therapy.
4 Major treatment problems are metastatic invasion, local
tumor recurrence, and multidrug resistance.
5 Therefore, it is not
only necessary to develop novel strategies to destroy cancer cells
efficiently, but also to attempt a stimulation of the immune
system in order to control residual tumor cells.
Macrophages play an important role in the defense against
tumors.
6,7 They have the capacity to recognize and destroy tumor
cells through several different mechanisms, including secretion of
tumor necrosis factor-a,
8 nitric oxide,
9 interleukin-1β,
10 and reac-
tive oxygen intermediates.
11 Furthermore, macrophages are
involved in the antibody-dependent cellular cytotoxicity in thera-
peutic approaches with recombinant antibodies.
12 Macrophage
cytotoxicity relies on the balance between activating stimuli and
suppressive signals.
One well known signal for engulfment by phagocyting cells is a
change in the composition of phospholipids on the target cells.
13
Furthermore, the interaction of calreticulin with the low-density
lipoprotein-related protein (LRP) plays also an important role
in apoptotic cell removal, resulting in an activation of the
macrophages.
14 Calreticulin is an intracellular calcium-binding
protein and anthracyclines are able to elicit it’s translocation onto
the cell surface.
15 On the other hand, the interaction between
CD47 and the signal regulatory protein a (SIRPa) is a key
function to protect viable cells from phagocytosis.
16 CD47, a
widely distributed inhibitory receptor on macrophages that can
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phagocytosis, serves as the ligand for SIRPa.
17 Overexpression
of inhibitory molecules like CD47 is a common mechanism
of tumor cells to escape phagocytosis. A high expression of
calreticulin or blocking of CD47 by mono-
clonal antibodies may shift the balance
between activating and inhibiting signals in
favor of phagocytosis.
18
The aim of this study was to describe the
distribution of CD47 and calreticulin in
human RMS and to analyze the cytotoxic
activity of GM-CSF activated macrophages
in combination with a CD47-blocking
monoclonal antibody (mAb). Furthermore,
we evaluated the effect of doxorubicin on
the interaction between RMS cells and
macrophages.
Results
Expression of CD47 and calreticulin on
RMS tissues and cells. In a first attempt to
evaluate the role of CD47 and calreticulin
in RMS, expression of these genes was
examined in RMS tissue samples by micro-
array analysis. CD47 inhibits phagocytosis
and its gene was expressed in the 11 RMS
tissue samples analyzed (Fig.1A). With a
fold change of 1.2, a significant higher
expression was observed in RMA compared
with RME tissues (p = 0.02; Student’s
t-test) and skeletal muscle biopsy samples
(p = 0.002; Student’s t-test). The macro-
phage activating gene calreticulin showed a
very high expression in the array analysis
of both RMA and RME, independent of
the histological subtype (median, 0.7).
Compared with muscle control tissues, a
significant higher expression was found
in RMS (p , 0.0001; Student’s t-test).
Accordingly, we detected high expression
levels of the proteins CD47 and calreticulin
on RMS tissue slices by immunofluores-
cence analysis (Fig.1B). In immunofluor-
escence staining, fewer differences between
RMA and RME samples were observed
with regard to the expression of CD47.
When examining CD47 on RMS cell lines
by flow cytometry, the protein was observed
on the cell surface of Rh30 and RD. Both
showed a high expression of CD47 as
revealed by staining with an anti-human
CD47 mAb (Fig.2A). Calreticulin could
not be detected on the cell membrane.
However, intracellular flow cytometry ana-
lysis revealed a low expression of calreticulin
both in Rh30 and RD cells. In these cell lines calreticulin seems to
be compartmentalized to the endoplasmatic reticulum, as revealed
by immunocytochemistry. In contrast to flow cytometry analysis,
the expression of calreticulin was high, which is in turn consistent
Figure1. Expression of CD47 and calreticulin in rhabdomyosarcoma and muscle tissue samples.
(A) Gene expression is shown for each tissue sample enrolled in the microarray expression analysis
relative to GAPDH. (***Student’s t-test p , 0.0001). (B) Immunofluorescence analysis of
representative RMS tissue sections using CD47 and calreticulin mAbs followed by the red
fluorescent secondary antibody and Hoechst 33342 for nuclear blue staining. As control served
RMS tissues incubated without primary mAb.
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low signal in flow cytometry might be a result of an
ineffective permeabilization of the endoplasmatic reti-
culum. The “don’t eat me” signal CD47 was strongly
expressed in RMS tissue samples of both histological
subtypes and on the cell surface of RMS cells. Therefore,
we next modulated the macrophage cytotoxic activity in
vitro using inhibitory antibodies.
Cytotoxic activity of macrophages modulated by anti-
CD47. The ability of human macrophages to phagocyte
allogeneic RMS cells in co-cultures at an E:T ratio of 2.5:1
was monitored for up to 96 h. After 24 h, a few poly-
nucleated cells were observed in the confluent grown
tumor cell culture (pictures not shown). Distinct holes in
the cell layer caused by phagocytosis were also observed
and photos were taken after 96 h (Fig.3A). No cell free
areas were detected in the control samples. The most and
largest holes in the tumor cell monolayer were present in
the cultures treated with the anti-CD47 mAb (Fig.3B).
When treated without antibody, Rh30 cells were more
efficiently phagocyted than RD cells with a cell free area of
4600 mm
2 compared with 2500 mm
2. Blocking CD47
with an anti-CD47 mAb increased the phagocytosis of
both RD cells and Rh30 cell cultures (17900 mm
2 and
12700 mm
2, respectively). In relation to the whole area of
151810 mm
2, a 5% increase in phagocytosis of Rh30 was
detected and the increment for RD was 10%.
By measuring cytotoxicity in co-cultures, we observed a
specific phagocytosis of both RMS cell lines again (Fig.4).
After co-culturing with macrophages at an E:T ratio of 2:1
for 24 h, 70% of Rh30 and 45% of RD cells remained
viable. When additionally treated with the anti-CD47
mAb, cell viability did not change significantly (Rh30:
80%; RD: 60%). As a control, exclusive antibody treat-
ment had no effect on Rh30 cell viability. In contrast, cell
viability of RD cells dropped to 85%. Taken together, the
phagocytosis of RMS cells could not be increased by
blocking of the inhibitory ligand CD47 using mAbs in
this short period of time. Therefore, we next investigated
other mechanisms to shift the balance between activating
and inhibiting signals in favor of phagocytosis.
Retrieving calreticulin to enhance phagocytosis.
Macrophages can be activated by the interaction of
calreticulin and LRP. Preliminary data has shown that
RMS cells do not express calreticulin on their surface
Figure2. CD47 and calreticulin expression in rhabdomyosar-
coma cell lines. (A) High expression of CD47 (black lines) but no
extracellular expression of calreticulin was detected on both
Rh30 and RD cells by flow cytometry. The control staining
without primary antibody is plotted on each panel as gray
histogram. Dead cells were gated out by their position in
forward and site scatter. (B) Expression of calreticulin shown by
intracellular flow cytometry analysis and immunocytochemistry
in the endoplasmatic reticulum of RMS cells. Secondary FITC-
labeled antibody and Hoechst 33342 for nuclear staining were
used. Controls were incubated without primary antibody.
www.landesbioscience.com OncoImmunology 281(Fig.2A). Therefore, we intended to induce the transport of
calreticulin to the RMS cell surface by using doxorubicin. The
IC50 for both RMS cell lines was determined to be 0.1 mg/ml
(Fig.5A). A lower concentration (0.01 mg/ml) was also tested in
flow cytometry and co-culture experiments, which on the one
hand had an effect on RMS cell viability (80% viability in an 96 h
assay), but on the other hand was low enough, to avoid massive
drug dependent cell death and to assess phagocytosis effects.
Cell surface presentation of calreticulin, depending on the
used doxorubicin concentration, was detected by flow cytometry
(Fig.5B). A higher expression was measured in RD cells com-
pared with Rh30. Thereupon, after treatment with the higher
concentration of doxorubicin (0.1 mg/ml) the co-culture experi-
ments with macrophages revealed an efficient phagocytosis of RD
cells up to 90% (Fig.6B). When additionally treated with the
anti-CD47 mAb (10 mg/ml), this effect could not be enhanced
(viability RD 15%). In Rh30 cells, a lysis of 65% was achieved
after treatment with the IC50 concentration of doxorubicin
(0.1 mg/ml). After co-culture with macrophages, the Rh30 cell
viability dropped without reference to the addition of the CD47
antibody to 35% and 40%, respectively (Fig.6A). Viability of
both RMS cell lines was half-reduced after treatment with the
lower dose of doxorubicin (0.01 mg/ml) and co-culture with
macrophages (viability of Rh30 55% and of RD 50%). These
results were no further influenced by the addition of the anti-
CD47 mAb (viability of Rh30 65% and of RD 55%). Four
different treatment options served as controls: (A) Co-culturing
with macrophages reduced the viability of Rh30 cells to 60% and
RD cells to 55%. (B) After antibody treatment and co-culture
with macrophages 65% of Rh30 and 60% of RD cells remained
viable. (C) Exclusive treatment with the previously evaluated IC50
of doxorubicin (0.1 mg/ml) resulted in a drop of cell viability
to 55% (Fig.5A). (D) Treatment with the lower tested drug
concentration (0.01 mg/ml) had no effect on the morphology and
viability of Rh30 cells (95%). However, survival of RD cells
dropped to 85% by doxorubicin alone. In summary, phagocytosis
of RMS cells was significantly enhanced by retrieving calreticulin
using the IC50 concentration of doxorubicin (two-way ANOVA,
p , 0.001).
The cause-effect relationship between doxorubicin treatment,
CRT exposure and enhanced susceptibility to cytotoxic effects
mediated by macrophages was demonstrated using a blocking
peptide to calreticulin. This peptide abrogated phagocytosis of
lymphoblast cell lines by macrophages.
19 In co-cultures of RMS
cells and macrophages, the enhanced phagocytosis achieved by
Figure3. Susceptibility of rhabdomyosarcoma cell lines to cytotoxicity by macrophages. (A) Rh30 and RD cells were co-cultured with macrophages for
96 h at an E:T ratio of 2.5:1. Indicated wells were pre-incubated with 10 mg/ml blocking antibody to CD47 for 30 min. Pictures show tumor cell free areas
in cultures with macrophages. (B) Cell lysis was quantified by measuring the cell free area in the tumor cell layer by an image analyzer system.
Figure4. Effect of CD47 antibody on the cytotoxicity of macrophages
against rhabdomyosarcoma cells. Co-cultures of Rh30 and RD cells
with macrophages (E:T 2:1) were performed after incubating the tumor
cells for 30 min with an anti-CD47 antibody (10 mg/ml). Cell viability was
then determined by MTT assay 24 h later. Data represent means ± SD
of relative cell viability from triplicates. Experiments without antibody
were set at 100% viability.
282 OncoImmunology Volume 1 Issue 3doxorubicin could be partially blocked by the blocking peptide
(Fig.7). Therefore, the effect of doxorubicin on the phagocytosis
of RMS seems to be mediated to some extent by calreticulin
exposure.
Discussion
Effective antibody targeting of CD47 has been demonstrated for
several human cancers including acute myeloid leukemia (ALL),
20
bladder cancer,
21 and non-Hodgkin lymphomas.
22 The thera-
peutic effect of blocking CD47 with antibodies is mediated
primarily through macrophage phagocytosis
23 and was observed
for ALL in vitro and in tumor engraftment in vivo.
24 Targeting
of tumor cells with antibodies against CD47 has previously
been reported to directly induce apoptosis.
25-28 Now the idea is
supported, that targeting CD47 may lead to a disruption of
the CD47-SIRPa interaction, thereby preventing a phagocytic
inhibitory signal.
20 CD47 was found to be highly expressed not
only on tumor cells but also on normal tissues.
29 However,
potential toxic effects with a CD47 antibody therapy could be
excluded.
24 Selective targeting of tumor cells is probably due to a
high cell surface expression of calreticulin. Indeed, calreticulin is
expressed in all cells, but only a low presentation was profiled on
the cell surface of healthy tissues. By contrast, for several human
cancers a high extracellular expression was demonstrated.
18
This data led us to speculate, that targeting CD47 will be a
promising tool against a wide range of human tumors, including
RMS. Our data revealed a high expression of CD47 on RMS
tissues and cells, which may play a role in the immune evasion of
RMS. Furthermore, a significant association between the higher
expression of CD47 and the more aggressive RMA subtype was
found in gene expression analysis. Interaction of RMS cells with
GM-CSF activated macrophages required more than four days of
incubation to reveal a notable phagocytosis. Enhanced cytotoxi-
city was only obtainable by increasing the proportion of
macrophages (data not shown). Usually, such assays with human
acute myeloid leukemia stem cells revealed a fast engulfment of
tumor cells within two hours of co-culture with stimulated
macrophages.
20 We therefore conclude that RMS cells are less
susceptible to phagocytosis by macrophages.
To enhance phagocytosis, we tried to disrupt the CD47-SIRPa
interaction with a mAb demonstrably able to specifically block
CD47.
30 In our short-term assay of 24 h, no enhancement of
phagocytosis was observed. This might be due to low activating
signals for the phagocytes. Besides the exposure of GM-CSF and
phosphatidylserine, which may interact with several phagocyte
receptors, calreticulin functions on tumor cells as a ligand for the
activating phagocyte receptor LRP/CD91.
13,16,31 Furthermore,
annexin-1 is under active investigation.
26
Figure5. Viability and calreticulin expression of rhabdomyosarcoma cells pre-treated with doxorubicin. (A) Rh30 and RD cells were incubated for
96 h with increasing doses of doxorubicin. Data are means ± SD of triplicate viability measurements using MTT assay. Experiments without doxorubicin
were set at 100% viability. (B) Extracellular calreticulin expression on Rh30 and RD cells was measured by flow cytometry after incubation for 24 h
with 0.01 mg/ml (dark gray line) or 0.1 mg/ml doxorubicin (dashed line). No calreticulin on the cell surface was detected without doxorubicin (black line).
The control staining without primary antibody is plotted on each panel as gray histogram.
Figure6. Phagocytosis of rhabdomyosarcoma cells after pre-treatment
with doxorubicin. As indicated, Rh30 (A) and RD cells (B) were incubated
with 0.01 mg/ml or 0.1 mg/ml doxorubicin (Doxo) for 24 h and CD47
antibody for 30 min. Macrophages were added at an E:T ratio of 2:1 and
cell viability was assessed using MTT assay 24 h later. Data are means ±
SD of relative viability from three experiments. Experiments without
antibody and doxorubicin were set at 100% viability.
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many stress proteins, among them calreticulin.
32 This leads to
increased amounts of calreticulin on the cell surface.
33 However,
the exact transport mechanism of calreticulin remains unclear.
Anthracyclines are able to induce the translocation of calreticulin
from the endosplasmatic reticulum onto the cell surface. The
presented results show a dose-dependent calreticulin presentation
after doxorubicin treatment. For colon carcinoma cells, a con-
centration of 25 mM doxorubicin, converted 14.5 mg/ml, was
described in the same incubation period.
15 For RMS cells, a
measureable extracellular calreticulin expression and a significantly
increased phagocytosis was demonstrated after incubation with
0.1 mg/ml doxorubicin. Furthermore, a different response of
RME compared with RMA cells was observed. Under equal
doxorubicin concentrations, the RME cells showed a higher
extracellular calreticulin presentation and accordingly a more
efficient phagocytosis compared with RMA. The role of
calreticulin in the doxorubicin enhanced phagocytosis was
demonstrated using a blocking peptide, which reversed the
activity of macrophages, although CD47 was expressed at high
density. A complete blockage can be expected in the absence of
CD47 as demonstrated for mutant lymphomas.
19
We could clearly demonstrate that macrophages are able to
phagocyte allogeneic RMS cells under conditions of cell-to-cell
contact. After GM-CSF activation of macrophages and co-
culturing with RMS cells, viability dropped to 50–60% without
any additional treatment. After activation of calreticulin, the
efficient phagocytosis of RME cells was enhanced to 90%.
This promising effect in vitro has to be verified in vivo.
Doxorubicin may improve the efficacy of adoptive cellular
immunotherapy and chemotherapy protocols. So far, doxorubicin
is used in combination with ifosfamide and vincristine in the
therapy protocol for the high risk soft tissue sarcoma group
(CWS-2002 P).
Material and Methods
Gene expression analysis. The gene expression data used in this
study were part of a microarray analysis described previously.
34
All patients were treated within the trials of the Cooperative
Soft Tissue Sarcoma Study (CWS) Group of the Society of
Pediatric Oncology and Hematology (GPOH). Mean age of
patients was 6.4 y (range 1 to 15 y, 95% CI of mean 4.2 to 8.8).
Histological analysis revealed 5 RMA and 6 RME. All cases
received central pathological review and patients were treated
according to the uniform protocols. Only samples with tumor cell
content of at least 80% were included for analysis. Metastases
were present at the time of surgery in all patients suffering from
RMA and in none in RME patients. Analysis of tissue samples
was approved by the local ethical committee (CWS 2002-P: 418/
2004V). As controls, data of skeletal muscle biopsies from
8 patients acquired on the same array platform were used.
35 The
expression of CD47 (probesets 211075_s_at and 213857_s_at on
the Affymetrix HG-U133 Plus 2.0 microarray) and calreticulin
(212953_x_at and 214315_x_at) was compared with the
housekeeping gene GAPDH (212581_x_at and 213453_x_at)
for each sample as fraction of the signal log ratio. Comparison of
relative expression in RMA, RME, and control tissue was
performed by Student’s t-test.
Cell lines and culture conditions. The RMA cell line Rh30
(DSMZ, ACC-489) as well as the RME cell line RD (ATCC,
CCL-136) were cultured in DMEM medium (Biochrom)
supplemented with 10% fetal bovine serum, 1% penicillin/
streptomycin, and 1% L-glutamine (Biochrom) in a humidified
atmosphere containing 5% CO2 at 37°C. All cells were tested
to be mycoplasma negative. Cell identity was proven by SLR
analysis of the DNA profile using PowerPlex 16 (Promega).
Flow cytometry analysis. Trypsinized cells were incubated for
30 min in FACS-buffer (PBS with 2% FBS, 2 mM EDTA,
0.005% NaN3; Sigma-Aldrich) containing anti-CD47 mAb
(B6H12; BD Biosciences). Intracellular flow cytometry of
calreticulin was performed with cells fixed in 3.7% formaldehyde
solution (Merck), and permeabilized by 0.2% Tween 20 in PBS
(Sigma-Aldrich). Primary antibody (anti-calreticulin, FMC 75;
Enzo Life Sciences) was added for 30 min diluted in FACS-buffer.
This was followed by a washing step with FACS-buffer and
cells were labeled with FITC-conjugated goat anti-mouse
IgG (Jackson ImmunoResearch). Data was acquired with
FACSCalibur (Becton Dickinson) and analyzed by FCS Express
(De Novo Software).
Figure7. RMS cells Rh30 (A) and RD
(B) were incubated with human
macrophages in culture media
alone or with calreticulin-blocking
peptide (4 mg/ml) for 24 h, after
which cell viability was analyzed
by MTT assay. Pre-treatment of RMS
cells with 0.01 and 0.1 ng/ml
doxorubicin resulted in increased
phagocytosis compared with
control cells. Blockade of calreticu-
lin on RMS cells partially abrogated
phagocytosis.
284 OncoImmunology Volume 1 Issue 3Immunofluorescence staining. RMS cells were first fixed with
3.7% formaldehyde solution to perform immunofluorescence
staining with anti-CD47 or anti-calreticulin mAbs. Additionally,
several sections from frozen specimens of RMS tumors were
analyzed. Cells and tissue slides were fixed for 5 min in a 1:1
acetone and methanol mixture (Merck) and washed in PBST
(PBS with 0.1% Tween 20, Sigma-Aldrich). Blocking was
performed using 1% normal goat serum (Dako Cytomation)
for 30 min followed by primary antibody diluted in PBST to
10 mg/ml. Slides were washed three times for 5 min in PBST.
Secondary Alexa 546-conjugated goat anti-mouse antibody
(1:500; Molecular Probes/Invitrogen) was added for 30 min at
room temperature, followed by three times washing for 5 min.
For counterstaining of the nucleus, Hoechst 33342 was used
(1:2000; Sigma-Aldrich). Slides were mounted with fluorescence
mounting medium (Dako Cytomation) and subsequently
analyzed by fluorescence microscopy (AxioVision; Carl Zeiss).
Cell proliferation. RMS cells (1  10
4) were seeded out in a
96-well plate. After incubation over night, serial 10-fold dilutions
of doxorubicin (Cell Pharm) ranging from 100 to 0.00001 mg/ml
were added (as shown in Fig.5). Cell viability was assessed 96 h
later by an MTT assay. Therefore, 25 ml of 12 mM MTT [3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyl tetrazolium bromide] (Sigma-
Aldrich) dissolved in PBS were added to each well containing
100 ml cell suspension. Incubation was stopped 3 h later with
100 ml of 10% SDS in acid water (Merck). Absorption was
measured at 570 nm after incubation over night using a Milenia
Kinetic Analyzer (DPC Biermann). All assays were performed
in triplicates. The percentage of viability was calculated by
normalization between background of cultures without cells and
untreated cultures as control experiments.
Generation of macrophages. Peripheral blood mononuclear
cells (PBMCs) isolated from buffy coats were plated into 25 ml
cell culture flasks in serum-free X-VIVO 20 medium (Lonza).
After 1 h of incubation at 37°C, non-adherent cells were removed
by washing twice in PBS. Adherent cells were then incubated in
RPMI 1640 supplemented with 10% fetal bovine serum, 1%
penicillin/streptomycin, 1% L-glutamine, 1% non essential
amino acids, and 1% sodium pyruvate (Biochrom) for 6 d with
medium changes every 48 h. On day 6, 50 U/ml GM-CSF (BD
Biosciences) were added to activate differentiated macrophages.
On day 7, cells were incubated for 5 min in PBS, scraped off with
a sterile cell scraper, collected by centrifugation, and re-suspended
in culture medium.
Phagocytic activity of macrophages. RMS (2  10
4) cells were
seeded out on a 96-well plate and incubated with 10 mg/ml anti-
CD47 mAb for 30 min. Afterwards, macrophages were added at
an effector to target (E:T) ratio of 2.5:1. Digital images were taken
at a 6.3-fold magnification with AxioCam MRc (Carl Zeiss) on a
Leitz Fluovert FS optical microscope (Leica) 24 and 96 h later.
The cell free area in the cell layer was measured using an image
analyzer system (AxioVision 3.1; Carl Zeiss).
RMS cells (1  10
4) were seeded out on a 96-well plate and
incubated with either 0.01 mg/ml or 0.1 mg/ml doxorubicin (Cell
Pharm) for 24 h. Cells were incubated for 30 min with 10 mg/ml
anti-CD47 mAb, as indicated. A blocking peptide to calreticulin
(MBL) at 4 mg/ml was added to the tumor cells.
19 Subsequently,
macrophages were added at an E:T ratio of 2:1. Target
phagocytosis was monitored after 24 h using MTT assay as
described previously. Percent viability was calculated by normal-
ization between background of cultures without cells and
untreated cultures as control experiments. When macrophages
were added, normalization was performed between background
of macrophages and untreated cultures. All experiments were
performed in triplicates.
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